ClinicalTrials.gg
Not yet recruitingNCT07847151MIND-AMDUpdated Sep 29, 2026

MIND-AMD Study: a Multidisciplinary Investigation of Neuroretinal Damage in Age-related Macular Degeneration.

An observational study in Age-Related (Dry) Macular Degeneration, Age-Related Macular Degeneration (AMD) and AMD Population - Intermediate or Advanced AMD, sponsored by IRCCS San Raffaele. Not yet recruiting. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.

Primary conditionMacular EdemaRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Macular Edema
Why
  1. The study's listed conditions name Macular Edema, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by IRCCS San Raffaele · Observational

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
160
Ages
50 Years and older
Sex
All
01

Study summary

Age-related macular degeneration (AMD) is the major cause of legal blindness in developed countries. Intermediate AMD represents the most frequent stage. However, it often evolves towards complicated stages, namely neovascular AMD or geographic atrophy (GA). Despite the available treatments, the visual outcome is highly heterogeneous. The scientific interest is growing regarding the assessment of neuroretinal changes in AMD. Although AMD is mainly considered an outer retinal disease, recent evidence suggests a major involvement of retinal glia and neurons, i.e. an involvement of the inner retina. This damage may remarkably affect the morphological and functional AMD outcome, subverting retinal signal transmission cascade and more clearly explaining the outcome of the disease. The main goal of this study is to perform a multidisciplinary, multicenter, both prospective and retrospective evaluation of neuroretinal degeneration in different AMD stages in preclinical and clinical models.

02

Conditions studied

  • Age-Related (Dry) Macular Degeneration
  • Age-Related Macular Degeneration (AMD)
  • AMD Population - Intermediate or Advanced AMD
  • AMD and Macular Edema
  • Neovascular (Wet) Age-Related Macular Degeneration

Browse trials for

Keywords

  • Age-related macular degeneration
  • Multimodal retinal imaging
  • Mouse model
  • microRNA
03

In context

Macular Edema Reclassified

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

This study's planned enrollment of 160 is above the median of 71 across 127 observational studies indexed under Macular Edema.

Browse Macular Edema studies →

Lead sponsor

IRCCS San Raffaele is the lead sponsor of 454 studies on the registry; 235 are open to participants now.

Compared within Macular Edema, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients affected by intermediate, wet and dry (geographic atrophy) age-related macular degeneration (AMD) and healthy age- and gender-matched controls

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of AMD

Exclusion criteria

Exclusion Criteria:

  • low BCVA (\<20/100)
  • other ocular diseases
  • uncontrolled systemic diseases potentially affecting data interpretation
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
160 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients affected by AMD (different stages)

    Patients affected by intermediate, wet and dry atrophic AMD

  • Healthy controls

    Healthy age- and gender-matched control

06

What researchers measure

Primary outcomes

  1. Neuroretinal degeneration quantitative metrics

    Quantitative multimodal retinal imaging metrics associated with inner retinal changes and neuroretinal degeneration

    Time frame: From January 2027 to January 2030

  2. Imaging metrics of neuroretinal changes

    Multimodal retinal imaging metrics associated with inner retinal changes and neuroretinal degeneration

    Time frame: From January 2027 to January 2030

  3. MicroRNA profiles associated with AMD stages

    MicroRNAs different profiles associated with AMD stages, risk of progression and neuroretinal degeneration.

    Time frame: From January 2027 to January 2030

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Natoli R, Fernando N. MicroRNA as Therapeutics for Age-Related Macular Degeneration. Adv Exp Med Biol. 2018;1074:37-43. doi: 10.1007/978-3-319-75402-4_5. PubMed 29721925 ↗
  • Nassisi M, Fan W, Shi Y, Lei J, Borrelli E, Ip M, Sadda SR. Quantity of Intraretinal Hyperreflective Foci in Patients With Intermediate Age-Related Macular Degeneration Correlates With 1-Year Progression. Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3431-3439. doi: 10.1167/iovs.18-24143. PubMed 30025092 ↗
  • Nassisi M, Baghdasaryan E, Borrelli E, Ip M, Sadda SR. Choriocapillaris flow impairment surrounding geographic atrophy correlates with disease progression. PLoS One. 2019 Feb 22;14(2):e0212563. doi: 10.1371/journal.pone.0212563. eCollection 2019. PubMed 30794627 ↗
  • Nassisi M, Lei J, Abdelfattah NS, Karamat A, Balasubramanian S, Fan W, Uji A, Marion KM, Baker K, Huang X, Morgenthien E, Sadda SR. OCT Risk Factors for Development of Late Age-Related Macular Degeneration in the Fellow Eyes of Patients Enrolled in the HARBOR Study. Ophthalmology. 2019 Dec;126(12):1667-1674. doi: 10.1016/j.ophtha.2019.05.016. Epub 2019 May 29. PubMed 31281056 ↗
  • Nassisi M, Tepelus T, Corradetti G, Sadda SR. Relationship Between Choriocapillaris Flow and Scotopic Microperimetry in Early and Intermediate Age-related Macular Degeneration. Am J Ophthalmol. 2021 Feb;222:302-309. doi: 10.1016/j.ajo.2020.04.018. Epub 2020 Apr 28. PubMed 32360341 ↗
  • Arrigo A, Aragona E, Battaglia Parodi M, Bandello F. Quantitative approaches in multimodal fundus imaging: State of the art and future perspectives. Prog Retin Eye Res. 2023 Jan;92:101111. doi: 10.1016/j.preteyeres.2022.101111. Epub 2022 Aug 4. PubMed 35933313 ↗
  • Arrigo A, Aragona E, Bianco L, Antropoli A, Berni A, Saladino A, Cosi V, Bandello F, Battaglia Parodi M. The Localization of Intraretinal Cysts Has a Clinical Role on the 2-Year Outcome of Neovascular Age-Related Macular Degeneration. Ophthalmol Retina. 2023 Dec;7(12):1069-1079. doi: 10.1016/j.oret.2023.07.025. Epub 2023 Jul 30. PubMed 37527760 ↗
  • Arrigo A, Aragona E, Battaglia Parodi M, Bandello F. Quantitative Multimodal Imaging Characterization of Intraretinal Cysts versus Degenerative Pseudocysts in Neovascular Age-Related Macular Degeneration. Ophthalmol Retina. 2024 Dec;8(12):1118-1126. doi: 10.1016/j.oret.2024.05.019. Epub 2024 Jun 6. PubMed 38848872 ↗
  • Arrigo A, Saladino A, Aragona E, Barresi C, Mularoni C, Bandello F, Battaglia Parodi M. Clinical and Imaging Biomarkers Associated with Outer Retinal Atrophy Onset in Exudative Age-Related Macular Degeneration: A Real-Word Prospective Study. Ophthalmol Ther. 2024 May;13(5):1185-1196. doi: 10.1007/s40123-024-00903-4. Epub 2024 Mar 6. PubMed 38446282 ↗
  • Arrigo A, Aragona E, Del Fabbro S, Balduzzi E, Parodi MB, Bandello F. Quantitative Optical Coherence Tomography Detection of New Neovascular Branches and Association With Exudation Recurrence in Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2024 Jun 3;65(6):30. doi: 10.1167/iovs.65.6.30. PubMed 38899961 ↗

Individual participant data

Plan to share: Yes — Scientific publications and international conferences.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jun 2029, 29 months later.

Of 44 observational studies under Macular Edema, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 52. This study's planned 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 29, 2026
StartEst.
Jan 2, 2027
Primary completionEst.
Jun 30, 2029
CompletionEst.
Jan 2, 2030
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07847151
Lead sponsor
IRCCS San Raffaele
Responsible party
Alessandro Arrigo (MD, PhD, Head of Imaging Unit, Ophthalmology Department, IRCCS San Raffaele) — Principal investigator
First posted
Sep 29, 2026
Start date
Jan 2, 2027 (estimated)
Primary completion
Jun 30, 2029 (estimated)
Completion
Jan 2, 2030 (estimated)
Last update
Sep 29, 2026

Study contacts

Alessandro Arrigo, MD, PhD
Contact
arrigo.alessandro@hsr.it
+390226433580
Adelaide Pina, MsC
Contact
pina.adelaide@hsr.it
Alessandro Arrigo, MD, PhD
principal investigator · IRCCS San Raffaele Scientific Institute, Milan, Italy

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion